In this issue of Hematology/Oncology Clinics, guest editors Drs. Jennifer R. Brown and Matthew S. Davids bring their considerable expertise to the topic of Chronic Lymphocytic Leukemia. Top experts provide in-depth perspectives on CLL, including basic biology, frontline and relapsed refractory treatments, mechanisms of resistance to targeted therapies, Richter’s transformation, and some of the common complications of the disease stemming from immune dysfunction-offering a state-of-the-art overview of the field to help optimize the care of patients with CLL.
Autonomous B-cell Receptor Signaling in Chronic Lymphocytic Leukemia The Chronic Lymphocytic Leukemia Epigenome: A Powerful and Stable Framework for Understanding Biological and Clinical Heterogeneity Frontline Treatment of Chronic Lymphocytic Leukemia with Continuous Bruton’s Tyrosine Kinase Inhibitors: A Comprehensive Overview First-line Therapy: Time-Limited Venetoclax Doublet Therapy Triplet Therapies in Chronic Lymphocytic Leukemia Measurable/Minimal Residual Disease: What Method and What Cut-Off? Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia Resistance to Bruton Tyrosine Kinase Inhibitors Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia Immunotherapy in Chronic Lymphocytic Leukemia Advances in the Understanding of Richter Transformation Autoimmune Cytopenias in Chronic Lymphocytic Leukemia Understanding and Managing Infectious Complications in Chronic Lymphocytic Leukemia
Comments (0)
Your review appreciation cannot be sent
Report comment
Are you sure that you want to report this comment?
Report sent
Your report has been submitted and will be considered by a moderator.